Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study

BACKGROUND: Cardiovascular risk attributable to bevacizumab (Avastin(®), BEV) for treatment of metastatic colorectal cancer (CRC) remains unclear. We conducted a population-based cohort study to assess the safety of BEV use among patients aged ≥65. PATIENTS AND METHODS: We identified CRC patients di...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Tsai, H.-T., Marshall, J. L., Weiss, S. R., Huang, C.-Y., Warren, J. L., Freedman, A. N., Fu, A. Z., Sansbury, L. B., Potosky, A. L.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2013
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3660079/
https://ncbi.nlm.nih.gov/pubmed/23429865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt019
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items